Fresenius Kabi introduces methocarbamol injection
Fresenius Kabi is launching methocarbamol injection, in a 100 mg per mL 10 mL vial presentation.
Methocarbamol injection is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.
“We are pleased to expand our anesthesia and analgesia portfolio with the introduction of Methocarbamol injection, a medication that can provide relief for people with acute, painful musculoskeletal conditions,” Fresenius Kabi USA president and CEO John Ducker said.
Methocarbamol injection is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.
“We are pleased to expand our anesthesia and analgesia portfolio with the introduction of Methocarbamol injection, a medication that can provide relief for people with acute, painful musculoskeletal conditions,” Fresenius Kabi USA president and CEO John Ducker said.